BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...biotechs based on research from his lab, including Hydra Biosciences Inc....
BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...in recent months. In December 2018, it acquired preclinical TRPA1 antagonists for chronic pain from Hydra Biosciences Inc....
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...developed its own; each model expresses a different combination of human SIGLECs. Palleon’s third platform, Hydra...
BioCentury | Dec 21, 2018
Company News

Lilly gains preclinical pain program from Hydra

...Eli Lilly and Co. (NYSE:LLY) acquired all assets related to Hydra Biosciences Inc.’s (Cambridge, Mass.) preclinical transient receptor...
...Hydra Biosciences Inc., Cambridge, Mass. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology Shannon Lehnbeuter Eli Lilly and Co. Hydra Biosciences Inc. Transient...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Dermatology

...steps include identifying and testing additional RNA-based or small molecule TRPA1 inhibitors in the models. Hydra Biosciences Inc....
BioCentury | Jul 14, 2016
Strategy

Borderless at Boehringer

...obesity Obesity Eureka Therapeutics Inc. Emeryville, Calif. 2015 Identify antibodies against intracellular cancer targets Cancer Hydra Biosciences Inc....
...Develop therapeutic antibodies using Crystal Bioscience's gel encapsulated microenvironment (GEM) and chicken immunization platforms Undisclosed Hydra...
BioCentury | May 11, 2015
Clinical News

HX-100: Phase I start

...This quarter, Hydra will begin a Canadian Phase I trial to evaluate single and multiple ascending...
...to evaluate single and multiple ascending doses of oral HX-100 in about 90 healthy volunteers. Hydra Biosciences Inc....
BioCentury | May 4, 2015
Company News

Boehringer Ingelheim, Hydra deal

...Boehringer partnered with Hydra to identify small molecule inhibitors of transient receptor potential (TRP) ion channels...
...diseases. Boehringer is responsible for global development and commercialization of compounds identified under the deal. Hydra...
...tiered royalties. The companies declined to provide further details. Boehringer Ingelheim GmbH , Ingelheim, Germany Hydra Biosciences Inc....
BioCentury | Apr 28, 2014
Company News

Hydra, Boehringer Ingelheim deal

...cation channel subfamily C member 4 (TRPC4) and TRPC5 to treat CNS diseases and disorders. Hydra...
...inhibitors through preclinical development, after which Boehringer will be responsible for global development and commercialization. Hydra...
...be eligible for milestones, plus tiered royalties. The companies declined to disclose further financial terms. Hydra...
BioCentury | Apr 25, 2014
Company News

Hydra, Boehringer in CNS deal

...potential cation channel subfamily C member 4 (TRPC4) and TRPC5 for CNS diseases and disorders. Hydra...
...inhibitors through preclinical development, after which Boehringer will be responsible for global development and commercialization. Hydra...
Items per page:
1 - 10 of 39
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...biotechs based on research from his lab, including Hydra Biosciences Inc....
BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...in recent months. In December 2018, it acquired preclinical TRPA1 antagonists for chronic pain from Hydra Biosciences Inc....
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...developed its own; each model expresses a different combination of human SIGLECs. Palleon’s third platform, Hydra...
BioCentury | Dec 21, 2018
Company News

Lilly gains preclinical pain program from Hydra

...Eli Lilly and Co. (NYSE:LLY) acquired all assets related to Hydra Biosciences Inc.’s (Cambridge, Mass.) preclinical transient receptor...
...Hydra Biosciences Inc., Cambridge, Mass. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology Shannon Lehnbeuter Eli Lilly and Co. Hydra Biosciences Inc. Transient...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Dermatology

...steps include identifying and testing additional RNA-based or small molecule TRPA1 inhibitors in the models. Hydra Biosciences Inc....
BioCentury | Jul 14, 2016
Strategy

Borderless at Boehringer

...obesity Obesity Eureka Therapeutics Inc. Emeryville, Calif. 2015 Identify antibodies against intracellular cancer targets Cancer Hydra Biosciences Inc....
...Develop therapeutic antibodies using Crystal Bioscience's gel encapsulated microenvironment (GEM) and chicken immunization platforms Undisclosed Hydra...
BioCentury | May 11, 2015
Clinical News

HX-100: Phase I start

...This quarter, Hydra will begin a Canadian Phase I trial to evaluate single and multiple ascending...
...to evaluate single and multiple ascending doses of oral HX-100 in about 90 healthy volunteers. Hydra Biosciences Inc....
BioCentury | May 4, 2015
Company News

Boehringer Ingelheim, Hydra deal

...Boehringer partnered with Hydra to identify small molecule inhibitors of transient receptor potential (TRP) ion channels...
...diseases. Boehringer is responsible for global development and commercialization of compounds identified under the deal. Hydra...
...tiered royalties. The companies declined to provide further details. Boehringer Ingelheim GmbH , Ingelheim, Germany Hydra Biosciences Inc....
BioCentury | Apr 28, 2014
Company News

Hydra, Boehringer Ingelheim deal

...cation channel subfamily C member 4 (TRPC4) and TRPC5 to treat CNS diseases and disorders. Hydra...
...inhibitors through preclinical development, after which Boehringer will be responsible for global development and commercialization. Hydra...
...be eligible for milestones, plus tiered royalties. The companies declined to disclose further financial terms. Hydra...
BioCentury | Apr 25, 2014
Company News

Hydra, Boehringer in CNS deal

...potential cation channel subfamily C member 4 (TRPC4) and TRPC5 for CNS diseases and disorders. Hydra...
...inhibitors through preclinical development, after which Boehringer will be responsible for global development and commercialization. Hydra...
Items per page:
1 - 10 of 39